Does meeting the medicine's licence guarantee an NHS prescription?

No. A licence describes permitted use; NHS commissioning can apply narrower eligibility and a phased rollout.

Start with the right indication

The MHRA distinguishes weight-management products such as Wegovy and Mounjaro from semaglutide brands authorised for diabetes. A familiar ingredient does not make the brands interchangeable. A registered healthcare professional must assess suitability, discuss benefits and risks, and issue a prescription before treatment is supplied.

England has a phased pathway

NHS England's tirzepatide guidance separates specialist-service access from phased primary-care delivery. People may meet NICE criteria without being in the cohort currently prioritised locally. A GP or weight-management service can explain assessment, referral and local delivery. A private prescription does not itself establish NHS entitlement.

Check your nation

England's implementation guidance is not a UK-wide access policy. Scotland has its own medicines advice and local services; Wales and Northern Ireland also require checks with their NHS services. Referral availability matters alongside eligibility. Use the pathway for where you receive care, rather than an eligibility statement from another nation.

Make a private quote useful

Request the ongoing medicine charge, consultation and review fees, delivery arrangements and who manages side effects. Compare the prescribed product and quantity, not just an introductory offer. Confirm that the service uses a legitimate pharmacy and explain any NHS or other private treatment to the prescriber so care can be coordinated.

Keep these four questions separate

Access

Prescription after clinical assessment

Funding

Nation-specific NHS pathways; private care also available

Cost context

Compare the ongoing package in GBP, including reviews

Regulatory source

MHRA

Compare health systems ↗

Explore our UK pharmacy price comparisons →

Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. MHRA: GLP-1 medicines for weight loss and diabetes
  2. NHS England: tirzepatide interim commissioning guidance
  3. Scottish Government: obesity prescribing guidance
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →